SMMT
Summit Therapeutics Inc.
Key Financials
Net Income
$-1079586000
↓ 387.8%
Operating Income
$-225998000
↑ 62.9%
Revenue
$0
NaN%
Total Liabilities
$92.3M
↑ 97.2%
Total Assets
$751.2M
↑ 72.5%
Cash & Equivalents
$225.3M
↑ 114.8%
EPS (Diluted)
$-1.44
↓ 364.5%
Shareholders' Equity
$658.9M
↑ 69.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 424B5 | 6/10/2026 | View on SEC |
| S-3ASR | 6/9/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 8-K | 6/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SMMT |
| Company Name | Summit Therapeutics Inc. |
| CIK | 1599298 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 305-203-2034 |